SAN DIEGO, July 11, 2002 (PRIMEZONE) -- Women First HealthCare, Inc. (Nasdaq:WFHC) has scheduled a conference call for today at 3:20 p.m. ET to discuss the impact of the recent action by the National Institutes of Health (NIH) to terminate its Women's Health Initiative (WHI) clinical trial of the effect of combination estrogen/progestin on women's health. Dr. Nathan Kase, Chairman and Executive Editor of the Women First Health Advisory Board, and Professor, Department of Obstetrics, Gynecology and Reproductive Science of the Mount Sinai School of Medicine, will be on the call to address medical issues and the opportunity created by the NIH action.
The conference call will be broadcast live on the Internet and will be accessible at womenfirst.com, Investor Relations, Conference Calls, http://www.irconnect.com/wfhc/pages/conference.html and at CCBN's www.companyboardroom.com. Windows Media Player is the required software plug-in and can be downloaded at no cost from both Web sites.
The conference call will be archived and available on the above Web sites for two weeks beginning at approximately 5 p.m. ET, Thursday, July 11, through 5:00 p.m. ET, Thursday, July 25. A telephone replay of the call will also be available during this same timeframe and will be accessible by calling (800) 642-1687 (domestic) or (706) 645-9291 (international), conference code No. 4892161.
Women First HealthCare, Inc. (Nasdaq:WFHC) is a San Diego-based specialty pharmaceutical company. Founded in 1996, its mission is to help midlife women make informed choices regarding their health care and to provide pharmaceutical products-the Company's primary emphasis-and lifestyle products to meet their needs. Women First HealthCare is specifically targeted to women age 40+ and their clinicians. Further information about Women First HealthCare can be found online at www.womenfirst.com, About Us and Investor Relations.